Compare ABEO & PCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABEO | PCAP |
|---|---|---|
| Founded | 1974 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 324.1M |
| IPO Year | 2005 | N/A |
| Metric | ABEO | PCAP |
|---|---|---|
| Price | $5.49 | $10.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 36.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $9.01 |
| 52 Week High | $7.54 | $11.42 |
| Indicator | ABEO | PCAP |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 58.84 |
| Support Level | $5.24 | $10.18 |
| Resistance Level | $5.54 | $10.25 |
| Average True Range (ATR) | 0.27 | 0.00 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 35.50 | 57.14 |
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
ProCap Acquisition Corp is a blank check company.